ENTPD1 and neoplasm: As immune cells infiltrating the tumor co-express CD39 in association with other co-inhibitory molecules (e.g., CTLA4 and PD-L1), a combinational approach targeting both CD39, CD73, and co-inhibitory molecules has been proposed.